Stryker Corporation $SYK Stock Purchased by Compass Capital Management Inc.

Compass Capital Management Inc. grew its holdings in Stryker Corporation (NYSE:SYK) by 5.0% during the 3rd quarter, HoldingsChannel reports. The firm owned 168,441 shares of the medical technology company’s stock after acquiring an additional 7,962 shares during the quarter. Stryker comprises about 2.9% of Compass Capital Management Inc.’s investment portfolio, making the stock its 20th biggest position. Compass Capital Management Inc.’s holdings in Stryker were worth $46,387,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of SYK. Marble Harbor Investment Counsel LLC grew its stake in Stryker by 3.9% during the third quarter. Marble Harbor Investment Counsel LLC now owns 29,932 shares of the medical technology company’s stock worth $8,243,000 after buying an additional 1,114 shares during the last quarter. Eurizon Capital SGR S.p.A. boosted its holdings in shares of Stryker by 16.3% in the 3rd quarter. Eurizon Capital SGR S.p.A. now owns 107,386 shares of the medical technology company’s stock worth $29,587,000 after acquiring an additional 15,048 shares in the last quarter. Nikulski Financial Inc. boosted its holdings in shares of Stryker by 6.1% in the 3rd quarter. Nikulski Financial Inc. now owns 8,762 shares of the medical technology company’s stock worth $2,413,000 after acquiring an additional 502 shares in the last quarter. R Squared Ltd bought a new stake in Stryker during the 3rd quarter worth approximately $351,000. Finally, Maryland State Retirement & Pension System grew its position in Stryker by 15.3% during the 3rd quarter. Maryland State Retirement & Pension System now owns 21,396 shares of the medical technology company’s stock worth $5,892,000 after acquiring an additional 2,835 shares during the last quarter. Institutional investors own 77.09% of the company’s stock.

Stryker Stock Performance

Stryker stock opened at $309.05 on Friday. The company has a market cap of $117.65 billion, a PE ratio of 32.91, a PEG ratio of 2.14 and a beta of 0.78. The company has a current ratio of 2.18, a quick ratio of 1.30 and a debt-to-equity ratio of 0.60. Stryker Corporation has a 1 year low of $267.00 and a 1 year high of $389.33. The company’s 50-day moving average is $292.30 and its two-hundred day moving average is $322.60.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, October 29th. The medical technology company reported $3.52 earnings per share for the quarter, missing the consensus estimate of $3.55 by ($0.03). Stryker had a net margin of 13.78% and a return on equity of 23.74%. The business had revenue of $6.52 billion during the quarter, compared to analyst estimates of $6.62 billion. During the same quarter in the prior year, the company earned $3.19 earnings per share. The company’s quarterly revenue was up 7.6% on a year-over-year basis. Equities analysts anticipate that Stryker Corporation will post 14.85 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have recently commented on SYK. UBS Group decreased their target price on Stryker from $400.00 to $382.00 and set a “buy” rating on the stock in a report on Monday, August 3rd. Citigroup reaffirmed a “market outperform” rating on shares of Stryker in a report on Friday, October 30th. Wolfe Research lowered shares of Stryker from an “outperform” rating to a “peer perform” rating in a research report on Thursday, August 13th. Citizens Jmp decreased their price target on shares of Stryker from $400.00 to $390.00 and set a “market outperform” rating on the stock in a research note on Friday, October 30th. Finally, Truist Financial restated a “hold” rating and issued a $305.00 price objective (down from $310.00) on shares of Stryker in a research report on Monday, November 2nd. Twenty-one analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $342.19.

Insider Buying and Selling at Stryker

In related news, Director Ronda E. Stryker sold 550,000 shares of Stryker stock in a transaction on Friday, November 6th. The stock was sold at an average price of $325.32, for a total transaction of $178,926,000.00. Following the completion of the sale, the director directly owned 1,701,375 shares of the company’s stock, valued at $553,491,315. The trade was a 24.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Debra King sold 826 shares of Stryker stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total value of $277,783.80. Following the sale, the insider directly owned 6,210 shares of the company’s stock, valued at approximately $2,088,423. This trade represents a 11.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 901,267 shares of company stock worth $297,123,701. Insiders own 4.60% of the company’s stock.

Stryker Company Profile

Stryker is a medical technology company that develops and sells products and services for healthcare providers. Its offerings include orthopedic implants and surgical equipment, neurotechnology and spine products, and medical and surgical equipment used in hospitals and other care settings. The company’s products also include patient-handling and emergency medical equipment, as well as instruments and technologies that support surgical procedures. Stryker serves healthcare customers in the United States and internationally.